1. Enumerate five agents of malaria in humans.
2. Describe in brief rapid diagnostic test (RDT) used for malaria and its advantages.
3. Mention the vaccine available for malaria.
10 marks · directive: Enumerate; Describe; Mention
The core of a good answer
Human malaria is caused by Plasmodium falciparum, P. vivax, P. ovale, P. malariae and the zoonotic P. knowlesi; rapid diagnostic tests detect parasite proteins (HRP2, specific to P. falciparum, lactate dehydrogenase and aldolase) in a fingerstick blood sample and are fast and easily deployed where there is no full laboratory; the WHO-backed vaccines are RTS,S (approved by WHO in 2021) and R21/Matrix-M (endorsed in 2023), both against P. falciparum.
An outline written by upsc.help, not an official UPSC answer; every fact checked by a separate review. How we work
What the question asks
Marks 5+3+2: list the five species with a feature each; describe what the RDT detects, its advantages and limitations; name the vaccines with the year of WHO approval.
Answer outline
Introduction
Malaria is spread by the bite of an infected female Anopheles mosquito. Microscopy of Giemsa-stained thick and thin blood films is the gold standard for diagnosis.
1. Five agents of human malaria
- Plasmodium falciparum: responsible for the vast majority of malaria deaths.
- Plasmodium vivax: liver hypnozoites can reactivate after weeks or months and cause relapse.
- Plasmodium ovale: also forms hypnozoites and relapses.
- Plasmodium malariae.
- Plasmodium knowlesi: a zoonotic species that causes malaria in macaques.
2. Rapid diagnostic test
- Principle: the test detects parasite proteins (antigens) in a fingerstick blood sample.
- Antigens: histidine-rich protein 2 (HRP2), specific to P. falciparum; parasite lactate dehydrogenase; aldolase.
- Advantages: fast; easily deployed to places without full diagnostic laboratories.
- Limitations: HRP2 persists in blood for up to five weeks after treatment, so a positive test may not mean current infection; P. falciparum strains with pfhrp2 deletions can be missed, and in April 2026 WHO prequalified pf-LDH-based tests for such areas.
3. Vaccine
- RTS,S: the first approved vaccine against P. falciparum; approved by WHO in 2021 after pilot programmes in Ghana, Kenya and Malawi starting in 2019.
- R21/Matrix-M: endorsed by WHO in 2023 for the prevention of malaria in children; 77 percent efficacy in initial trials.
Conclusion
Correct species identification, quick antigen-based testing and the new vaccines are complementary tools in malaria control.
Examples and data to cite
- RTS,S was approved after pilot programmes in Ghana, Kenya and Malawi that began in 2019.
- Where more than 5 percent of cases are missed because of pfhrp2 deletions, WHO recommends pf-LDH-based RDTs.
Facts to remember
- Five species of Plasmodium commonly infect humans.
- HRP2 is specific to Plasmodium falciparum.
- WHO approved RTS,S in 2021 and endorsed R21/Matrix-M in 2023.
- A microscopist can detect parasites at 100 or more parasites per microlitre of blood.